Orchard Therapeutics announces second closing of strategic financing, resulting in $34m of additional capital

Orchard Therapeutics, a global gene therapy leader, today announced that it has completed the second closing of its previously announced securities purchase agreement, resulting in $34m of new capital before placement agent and transaction fees.

In March 2023, the company completed the first closing of an innovative financing arrangement, led by RA Capital Management with participation from other leading healthcare investors that resulted in $34m of new capital before placement agent and transaction fees. Per the terms of the agreement, the company could bring in an aggregate of up to $188m (inclusive of the $68m raised at the first and second closings) at increasing valuations following the achievement of certain U.S. regulatory milestones for OTL-200 for MLD.

Read the full news update on the Orchard Therapeutics website.